Непереносимоть терапии ингибиторами тирозинкиназ у больных хроническим миелолейкозом
Диссертация
Механизмы, лежащие в основе развития резистентности к иматинибу при XMJI, разнообразны. Их можно разделить на связанные и несвязанные с BCR-ABL-тирозинкиназой. В первую группу относятся амплификация и повышенная экспрессия гена BCR-ABL, мутации гена BCR-ABL, появление дополнительных хромосомных аберраций, во вторую — избыточное связывание иматиниба с транспортными белками крови (например… Читать ещё >
Список литературы
- Баркаган, З.С. Диагностика и контролируемая терапия нарушений гемостаза / З. С. Баркаган, А. П. Момот. М.: Ньюамед, 2001. — 296 с.
- Бутенко, З.А. Цитохимия и электронная микроскопия клеток крови и кроветворных органов / З. А. Бутенко, Д. Ф. Глузман. Киев: Наука думка, 1974.-248 с.
- Виноградова, O.A. Клиническая эволюция хронического миелолейкоза в процессе лечения ингибиторами тирозинкиназ: автореф. дис.. д-ра мед. наук: 14.01.21 / O.A. Виноградова. М., 2011. -45 с.
- Волкова, М.А. Клиническая онкогематология / М. А. Волкова. М.: Медицина, 2007. — 1120 с.
- Домрачева, Е.В. Прогностическое значение дополнительных цитогенетических аномалий при хроническом миелолейкозе / Е. В. Домрачева, А. Е. Захарова, Е. А. Асеева // Гематология и трансфузиология. -2005.-Т. 50, № 4.-С. 37−41.
- Дополнительные хромосомные аберрации у больных хроническим миелолейкозом / И. С. Мартынкевич, Л. С. Мартыненко, М. П. Иванова и др. // Гематология и трансфузиология. 2007. — Т. 52, № 2. — С. 28−35.
- Достижения в диагностике и лечении больных хроническим миелолейкозом в Российской Федерации (2004—2008 гг.) / Г. А. Туркина, О. Ю. Виноградова, Н. Д. Хорошко, А. И. Воробьёв // Бюллетень сибирской медицины. 2008. -№ 3. Прил. — С. 76−80.
- Клинические рекомендации Российской ассоциации эндокринологов по диагностике и лечению аутоиммунного тиреоидита у взрослых / И. И. Дедов,
- Г. А. Мельниченко, Г. А. Герасимов и др. // Клин, тиреоидология. 2003. -№ 1. — С. 24−25.
- Jlynna, X. Основы гистохимии / X. Луппа. М.: Мир, 1980. — 343 с.
- Момот, А.П. Патология гемостаза принципы и алгоритмы клинико-лабораторной диагностики / А. П. Момот. СПб.: Форма Т, 2006. — 220 с.
- Нефрология: Национальное руководство / под ред. H.A. Мухина М.: ГЭОТАР-Медиа, 2011. — 720 с.
- Осечинский, • И. В. Закономерности возникновения гемобластозов: автореф. дис.. д-ра мед. наук: 14.01.21 / И. В. Осечинский. М., 1981. — 55 с.
- Папаян, Л.П. Новое в представлении процесса свертывания крови / Л. П. Папаян // Трансфузиология. 2004. — Т. 5, № 3. — С. 7−22.
- Реброва, О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA / О. Ю. Реброва. М.: Медиа Сфера, 2002.-312 с.
- Руководство по гематологии: в 3 т. / под ред. А. И. Воробьев. 2-е изд. — Т. 2.- М.: Ньюдиамед, 2003. 247 с.
- Сизякина, Л.П. Справочник по клинической иммунологии / Л. П. Сизякина, И. И. Андреева. Ростов н/Д: Феникс, 2005. — 448 с.
- Струтынский, A.B. Электрокардиограмма: анализ и интерпретация / A.B. Струтынский. М.: МЕДпресс-информ, 2001. — 224 с.
- Струтынский, A.B. Эхокардиограмма: анализ и интерпретация / A.B. Струтынский. М.: МЕДпресс-информ, 2003. — 208 с.
- Хронический миелолейкоз: клинические рекомендации ESMO (Европейского общества Клинической Онкологии) по диагностике, лечениюи наблюдению: пер. с англ. М.: Издательская группа РОНЦ им. Н. Н. Блохина РАМН, 2010.-436 с.
- A new prognostic score for survival of patients with chronic myeloid leukaemia treated with interferon alfa / J. Hasford, M. Pfirrmann, R. Hehlmann et al. // J. Natl. Cancer. Inst. 1998. — Vol. 90, N 11. — P. 850−858.
- A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma / J.W. De Groot, B.A. Zonnenberg, P.Q. van Ufford-Mannesse et al. // J. of Clin. Endocrinol, and Metabol. 2007. — Vol. 92, N 9. — P. 3466−3469.
- A 10-year median follow-up study after allergenic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors / M. Robin, P. Guardiola, A. Devergie et al. // Leukemia. 2005. — Vol.19, N 9. — P. 1613−1620.
- Alternate pathways of thyroid hormone metabolism / S.Y. Wu, W.L. Green, W.S. Huang et al. // Thyroid. 2005. — Vol. 15, N 8. — P. 943−958.
- An evaluation of the cardiotoxicity of imatinib mesylate / A.L. Ribeiro, M.S. Marcolino, H.N. Bittencourt et al. // Leuk. Res. 2008. — Vol. 32, N 12. — P. 1809−1814.
- Astaldi, G. The glycogen content of the cells of lymphatic leukaemia / G. Astaldi, L.J. Verga // Acta haematol. 1957. — Vol. 173. — P. 129−135.
- Autografting in chronic myeloid leukemia: a meta-analysis of six randomized trials / M. Richards, J. Apperley, A. Carella et al. // J. Hematologica. 2005. — Vol. 90, Suppl 2. — P. 152−153.
- Autoimmune hemolytic anemia in Philadelphia positive chronic myeloid leukemia with t (7- 14) anomaly after 5 years of interferon alpha treatment / A. Koksal, D. Ozatli, I.C. Haznedaroglu et al. // Haematologia. 2002. — Vol. 32, N 2. — P. 163−167.
- Autoimmune Thrombocytopenia in Chronic Myeloid Leukemia Treated with Interferon-alpha: Differential Diagnosis and Possible / Y. Herishanu, S. Trestman, I. Kirgner et al. //Pathogenesis. -2003. Vol. 44, N 12. — P. 2103−2108.
- Azam, M. Mechanisms of autoinhibition and STI571imatinib resistance revealed by mutagenesis of BCR-ABL / M. Azam, R.R. Latek, G.Q. Daley // Cell. 2003. -Vol. 112, N6.-P. 831−843.
- Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cells / J. Durig, C. Rosenthal, A. Elmaagacli et al. // Leukemia. -2000. Vol. 14, N 9. — P. 1652−1660.
- Biswas, S.K. Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-Kinase/Akt survival signaling in RGC-5 retinal ganglion cells / S.K. Biswas, Y. Zhao, L. Sandirasegarane // J. Mol. Vis. 2009. — Vol. 15. — P. 15 991 610.
- BNP as a marker of the heart failure in the treatment of imatinib mesylate / Y.H. Park, H.I. Park, B.S. Kim et al. // Cancer Lett. 2006. — Vol. 243, N 1. — P. 1622.
- Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia BELA trial: 24-month follow-up Blood (ASH Annual Meeting Abstracts) / I. Cortes, A. Maru, CAAD Souza et al. // Blood. — 2011. — Vol. 118, N2.-Abstr. 455.
- Busulfan in the treatment of chronic myelocytic leukemia. The effect of long-term intermittent therapy / A. Haut, W.S. Abbot, M.M. Wintrobe, G.E. Cartwright // Blood. 1961.-Vol. 17.-P. 1−19.
- Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia / J.C. Barton, S.C. Jones, W.C. Lamberth et al. // Am. J. Hematol. 2002. — Vol. 71.-P. 139−140.
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib / T.F. Chu, M.A. Rupnick, R. Kerkela et al. // Lancet. 2007. — Vol. 370, N 9604. — P. 20 112 019.
- Cardiotoxicity of the cancer therapeutic agent imatinib mesylate / R. Kerkel, L. Grazette, R. Yacobi et al. // Nat. Med. 2006. — Vol. 12, N 8. — P. 908−916.
- Characteristic of accelerated diseasein chronic myelogenous leukemia / H.M. Kantarjian, M.J. Keating, R.S. Walters et al. // Cancer. 1988. — Vol. 61, N 7. -p. 14 411 446.
- Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders / F. Bonifazi, A. de Vivo, G. Rosti et al. // Blood. 2001. — Vol. 98, N 10.-P. 3074−3081.
- Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up / F. Palandri, F. Castagnetti, N. Testoni et al. // Haematologica. 2008. — Vol. 93, N 12. — P. 1792−1796.
- Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression / S. Marktel, D. Marin, N. Foot et al. // Haematologica. 2003. — Vol. 88, N 3. — P. 260−267.
- Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net / M. Baccarani, J. Cortes, F. Pane et al. // J. Clin. Oncol. 2009. — Vol. 27, N 3 5. — P. 6041 -6051.
- Cockcroft, D.W. Prediction of creatinine clearance from serum creatinine / D.W. Cockcroft, M.H. Gault // Nephron. 1976. — Vol. 16, N 1. — P. 31 -41.
- Common Terminology Criteria for Adverse Events (CTCAE), version 4.03 Electronic resource. / ed. by the National Cancer Institute. Published on June 14. — 2010. — Mode of access: http://evs.nci.nih. gov/ftpl/CTCAE/CTCAE. -23.08.2013.
- Concurrent megakaryocyte and erythroid chronic myelogenous leukemia blast crisis / E. Danielle, Westfall, Ling Zhang et al. // Arch, of Pathol. & Labor. Med.- 2008. Vol. 132, N 6. — P. 1021−1025.
- Concurrent Megakaryocyte and Erythroid Chronic Myelogenous Leukemia Blast Crisis / E. Westfall, L. Zhang, S. Song et al. // Arch, of Pathol, and Labor. Med.- 2008. Vol. 132, N 6. — P. 1021−1025.
- Congestive heart failure is arare event in patients receiving imatinib therapy / E. Atallah, J.B. Durand, H. Kantarjian, J. Cortes // Blood. 2007. — Vol. 110, N 4. -P. 1233−1237.
- Cortez, D. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis / D. Cortez, L. Kadlec, A.M. Pendergast //J. Mol. Cel. Biol.- 1995.-Vol. 15, N 10.-P. 5531−5541.
- Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias / M. Talpaz, N.P. Shah, H.M. Kantarjian et al. // N. Engl. J. Med. 2006. — Vol. 354, N24.-P. 2531−2541.
- Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib / A. Hochhaus, M. Baccarani, M. Deininger et al. // Leukemia. 2008. — Vol. 22, N6.-P. 1200−1206.
- Dasatinib .induces notable hematologic and cytogenetic responsec in chronic phase chronic myeloid leukemia after failure of imatinib therapy / A. Hochhaus, H. Kantarjian, M. Baccarani et al. // Blood. 2007. — Vol. 109, N 6. — P. 2303−2309.
- Dasatinib or high dose imatinib for chronic phase chronic myeloid leukemia after failure of first line imatinib: a randomized phase 2 trial / H. Kantarjian, R. Pasquini, N. Hamerschlak et al. // Blood. 2007. -Vol. 109, N 12. — P. 51 435 150.
- Deininger M.N. Chronic myeloid leukemia. Management of early stage disease / M.N. Deininger // Hematology. Am. Soc. Hematol. Atlanta, 2005. — P. 174−182.
- Deininger, M.W. The molecular biology of chronic myeloid leukemia / M.W. Deininger, J.M. Goldman, J.V. Melo // Blood. 2000. — Vol. 96, N 10. — P. 33 433 356.
- Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate / G.N. Mattiuzzi, J.E. Cortes, M. Talpaz et al. // Clin. Cancer Res. 2003. — Vol. 9, N 3. — P. 976−980.
- D’Hondt, L. Hypothyroidism and arthritis during interferon therapy / L. D’Hondt, A. Delannoy, C. Docquier // Clin. Rheumat. 1993. — Vol. 12, N 3. — P. 415−417.
- Early Imatinib Mesylate-Induced Hepatotoxicity in Chronic Myelogenous Leukaemia / .T.H. Konga, S.-H. Yooa, K.E. Lee et al. // Acta Haematol. 2007. -Vol. 118, N4.-P. 205−208.
- Effects of imatinib and interferon on primitive chronic myeloid leukemia progenitors / G.R. Angstrich, W. Matsui, C.A. Huff et al. // Br. J. Haematol. -2005.-Vol.130, N3.-P. 373−381.
- Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors / G.D. Demetri, M. von Mehren, C.D. Blanke et al. // N. Engl. J. Med. -2002. Vol. 347, N 7. — P. 472−480.
- Efficacy and safety of specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia / B.J. Druker, M. Talpaz, J. Debra et al. // N. Engl. J. Med. -2001. Vol. 344, N 14. — P. 1031−1037.
- Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP) / J. Cortes, S. O’Brien, A. Pardanani et al. // Blood. 2008. — Vol. 112. — Abstr. 182.
- Efficacy of dasatinib with presiously untreated chronic myelogenous leukemia in early chronic phase / J. Cortes, G. Borthakur, S. O’Brien et al. // Blood. 2009. -Vol. 114, N22.-Abstr. 338.
- Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase / H.M. Kantarjian, R.A. Larson, F. Guilhot et al. // Cancer. 2009. -Vol. 115, N3.-P. 551−560.
- Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma / K. Frank-Raue, M. Fabell, S. Delorme et al. // Eur. J. Endocrinol. 2007. — Vol. 157, N2.-P. 215−220.
- Elevated levels of the plasma protein alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis mediate pharmacological resistance to
- Gleevac (ST1571, imatinib) in vitro and are associated with primary resistance in vivo / J. Larghero, F.X. Mahon, I. Madeleine-Chambrin et al. // Blood. 2001. -Vol. 98.-P. 2582−2586.
- Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of European Lukemia Net / M. Baccarani, G. Saglio, J. Goldman et al. // Blood. 2006. — Vol. 108, N 6. — P. 1809−1820.
- Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment / K. Ikeda, Y. Shiga, A. Takahashi et al. // Leuk. Lymphoma. 2006. — Vol. 47, N l.-P. 155−157.
- Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones / Y.L. Chee, M.A. Vickers, D. Stevenson et al. // Leukemia. 2003. — Vol. 17, N 3. -P. 634−635.
- Fialkow, P.J. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage / P.J. Fialkow, R.J. Jacobson, T. Papayannopoulou // Am. J. Med. 1977. — Vol. 63, N l.-P. 125−130.
- First case of immunemediated haemolytic anaemia associated to imatinib mesylate / M. Novaretti, G. Fonseca, M. Conchon et al. // Eur. J. Haematol. 2003. — Vol. 71, N6.-P. 455−458.
- Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate / E. Jabbour, H. Kantarjian, D. Jones et al. // Leukemia. 2006. — Vol. 20, N 10. — P. 1767−1773.
- Frequency of major molecular response to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia / T.P. Hughes, J. Kaeda, S. Brandford et al. // N. Engl. J. Med. 2003. — Vol. 349, N 15. — P. 1423−1432.
- Functional consequence of MDR1 expression on imatinib intracellular concentrations / F.X. Mahon, F. Belloc, V. Lagarde, C. Chollet // Blood. 2003. — Vol. 102, N 3. — P. 1142−1162.
- Ghofrani, H.A. Imatinib for the treatment of pulmonary arterial hypertension / H.A. Ghofrani, W. Seeger, F. Grimminger // N. Engl. J. Med. 2005. — Vol. 353, N 13.-P. 1412−1413.
- Goldman, J. Management of chronic myeloid leukemia / J. Goldman /7 Semin. Hematol.-2003.-Vol. 40.-P. 1−103.
- Gottardi, M. Imatinib and hyperlipidemia / M. Gottardi, E. Manzato, F. Gherlinzoni // N. Engl. J. Med. 2005. — Vol. 353, N25.-P. 2722−2723.
- Graham, G.S. Peroxidase reaction for general differentiation / G.S. Graham, W. Knoll // Sandoz Atlas of Haematology / ed. by E. Undritz. 2-nd ed. — Basle: Sandoz, 1973.-P. 32.
- Gynecomastia in men with chronic myeloi leukemia after imatinib / K. Gambacorti-Passerini, L. Tornaghi, F. Cavagnini et al. // Lancet. 2003. — Vol. 361, N 9373.-P.1954−1956.
- Hayhoe, F.G.J. Cytochemical demonstration and measurement of leukocyte alkaline phosphatase activity in normal and pathological states by a modified Azo-Dyc Coupling Technique / F.G.J. Hayhoe, D. Quaglino // Br. J. of Hematol. -1959.-Vol.4.-P. 375.
- Hensley, M.L. Imatinib treatment: specific issues related to safety, fertility and pregnancy / M.L. Hensley, J.M. Ford // J. Sem. In. Hematol. 2003. — Vol. 40, N 2. Supple 2.-P. 21−25.
- Herpes zoster complicating imatinib mesylate for gastrointestinal stromal tumour / M.A. Durosinmi, P.O. Ogbe, L. Salawu, A.A. Oyekunle // Int. Med. 2005. — Vol. 44.-P. 114−119.
- High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-alpha / J.L. Steegmann, M.J. Requena, P. Martin-Regueira et al. // Am. J. Hematol. 2003. — Vol. 72, N 3. — P. 170−176.
- High-dose imatinib in newly diagnosed chronic phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses / J. Cortes, H. Kantarjian, S. Goldberg et al. // J. Clin Oncol. 2008. — Vol. 20. — P. 3869.
- High-dose imatinib mesylate therapy in newly diagnosed philadelphia chromosome positive chronic myeloid leukemia / H. Kantarjian, M. Talpaz, S. O’Brien et al. // Blood. 2004. — Vol. 103, N 8. — P. 2873−2878.
- Hochhaus, A. Imatinib therapy in chronic myeloid leukemia: strategies to avoid and overcome resistance / A. Hochhaus, P. La Rosee // Leukemia. 2004. — Vol. 18, N8.-P. 1321−1331.
- Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors / J. Desai, L. Yassa, E. Marqusee et al. // Ann. of Int. Med. 2006. — Vol. 145, N9.-P. 660−664.
- Hypothyroidism related to tyrosine kinase inhibitors: an underdiagnosed disorder? / T. Azevedo, M. Martinho, T. Martins et al. // Endocrine Abstracts. 2010. -Vol. 22.-P. 835.
- Imatinib (Gleevecjr)-induced hepatotoxicity / W.S. Ayoub, S.A. Geller, T. Tran et al. // J. Clin. Gastroenterol. 2005. — Vol. 39, N 1. — P. 75−77.
- Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia / S.G. O’Brien, F. Guilhot, R.A. Larson et al. // N. Engl. J. Med. 2003. — Vol. 348, N 11. — P. 994−1004.
- Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study / M.
- Talpaz, R.T. Silve, B J. Druker et al. // Blood. 2002. — Vol. 99, N 6. — P. 19 281 937.
- Imatinib induces hypothyroidism in patients receiving levothyroxine / J.W. De Groot, B.A. Zonnenberg, J.T. Plukker et al. // Clin. Pharmacol, and Ther. 2005. -Vol. 78, N4.-P. 433−438.
- Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner / R. Seggewiss, K. Lore, E. Greiner et al. // Blood. -2005. Vol. 105, N 6. — P. 2473−2479.
- Imatinib Mesylate (Gleevec) Hepatotoxicity / A.L. Mindikoglu, A. Regev, P.A. Bejarano etal.//J. Dig. Dis. Sci. 2007. — Vol. 52, N2.-P. 598−601.
- Imatinib mesylate (sti-571) attenuates liver fibrosis development in rats / H. Yoshiji, R. Noguchi, S. Kuriyama et al. // Am. I. Physiol. Gastrointest Liver. Physiol. -2005. Vol. 288, N 5. — P. 907−913.
- Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells / S. Appel, A.M. Boehmler, F. Grunebach et al. // Blood. 2004. — Vol. 103, N 2. — P. 538−544.
- Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis / J.H. Distler, A. Jungel, L.C. Huber et al. //Arthritis Rheum. 2007. — Vol. 56, N l.-P. 311−322.
- Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections / S. Mumprecht, M. Matter, V. Pavelic, A.F. Ochsenbein // Blood. 2006. — Vol. 108, N 10. — P. 34 063 413.
- Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia / C.E. Bueso-Ramos, J. Cortes, M. Talpaz et al. // Cancer. -2004.-Vol. 101, N2.-P. 332−336.
- Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study / R.A. Larson, B.J. Druker, F. Guilhot et al. // Blood. 2008. — Vol. 111, N 8. — P. 4022−4028.
- Immature leukemic CD34+CXCR4+cells from CML patients have lower integrin dependent migration and adhesion in response to the chemokine SDF-1 / A. Peled, I. Hardan, L. Trakhtenbrot et al. // J. Stem. Cells. 2002. — Vol. 20, N 3. — P. 259−266.
- Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600mg/day of imatinib as initial therapy / T. Hughes, S. Branford, D.L. While et al. // Blood. 2008. — Vol. 112, N 10. — P. 3965−3972.
- In vitro activity of bcr-abl inhibitors AMN107 and BMS-354 825 against clinically relevant imatinib-resistant abl-kinase domain mutants / T. O’Hare, D.K. Walters, E.P. Stoffregen et al. // Cancer Res. 2005. — Vol. 65, N 11. — P. 4500−4505.
- Interferon-alfa for chronic myeloid leukemia / M. Baccarani, D. Russo, G. Rosti et al. // Semin. Hematol. 2003. — Vol. 40, N 1. — P. 22−33.
- Intramuscular edema as a complication of treatment with imatinib / C. Shimazaki, N. Ochiai, R. Uchida et al. // Leukemia. 2003. — Vol. 17, Issue 4. — P. 804−805.
- JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis / L.S. Steelman, S.C. Pohnert, J.G. Shelton et al. // Leukemia. 2004. — Vol. 18, N 2. — P. 189−218.
- Kantarjian, H. Treatment of chronic myelogenous leukemia: current status and investigational options / H. Kantarjian, S. O’Brien, P. Anderlini // Blood. 1996. -Vol. 87, N8.-P. 3069−3081.
- Kaplow, L.S. A Histochemical Procedure for Localizing and Evaluating Leukocyte Alkaline Phosphatase Activity in Smears of Blood and Marrow / L.S. Kaplow // Blood. 1−955. — Vol. 10, N 10. — P. 1023−1029.
- Kay, J. Imatinib mesylate treatment of nephrogenic systemic fibrosis / J. Kay, W.A. High // Arthritis Rheum. 2008. — Vol. 58, N 8. — P. 2543−2548.
- Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients / J.M. Dora, M.A. Leie, B. Netto et al. // Eur. J. of Endocrinol. 2008. -Vol. 158, N5.-P. 771−772.
- Lin, H. et al. //Blood. -2011. -Vol. 118, № 10.-Abstr. 2743.
- Manley, P.W.// Blood. -2011. -Vol. 118, N 10. Abstr. 2746.
- McManus, J.F.A. Histochemical Demonstration of Mucin after Periodic Acid / J.F.A. McManus // Nature. 1946. — Vol. 158. — P. 202.
- Mechanism of disease: the biology of chronic myelogenous leukemia / S. Faderl, M. Talpaz, Z. Estrov et al. // N. Engl. J. Med. 1999. — Vol. 341, N 3. — P. 164 172.
- Molecular and chromosomal mechanisms of resistance to imatinib (STI 571) therapy / A. Hochhaus, S. Kreil, A.S. Corbin et al. // Leukemia. 2002. — Vol. 16, N 11.- P. 2190−2196.
- Mozziconacci, M.J. Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case / M.J. Mozziconacci, S. Cailleres, C. Maurice // Leukemia. 2003. — Vol. 17, Issue 9. -P. 1901−1902.
- Mustjoki, S. etal.//Blood.-2011.-Vol. 118, N 14. Abstr. 3765.
- Myeloid Dysplasia: the Histopathology of Preleukemia / A. Georgii, J. Thiele, K.-F. Vykoupil et al. // J. of Haematol, and Blood Transfus. 1981. — Vol. 26. — P. 34−37.
- National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification // Am. J. Kidney Dis. -2002. Vol. 39, Suppl. 1. — P. 1−266.
- Nel, A.E. T-cell activation through the antigen receptor, part 1: signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse / A.E. Nel // J. Allergy Clin. Immunol. 2002. — Vol. 109, N 5. -P. 758−770.
- Nievergall, E. et al.//Blood. 2011. — Vol. 118, N 14. — Abstr. 3745.
- Nilotinib can override dasatinib resistance in chronic myeloied leukemia patients with secondary resistance to imatinib first-line therapy / M. Breccia, L. Cannella, M. Nanni et al. // Acta Hematol. 2007. — Vol. 118, N 3. — P. 162−164.
- Nilotinib in chronic myelogenous leukemia in blast crisis (CML-BC) patients with imatinib resistance or intolerance: update phase II results / F. Giles, H.M. Kantarjian, L. Wunderle et al. // J. Clin. Oncol. 2008. — Vol. 26. — P. 7012.
- Nilotinib in chronic myeloid leukemia patients in accelerated phase with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study / A. Hochhaus, F. Giles, J. Apperlay et al. Il Haematologica. 2009. — Vol. 256. -Abstr. 631.
- Nilotinib is highly effective and safe in chronic myelogenous leukemia patients with imatinib resistance and intolerance / H. Kantarjian, F. Giles, N. Gattermann et al. //Blood. -2007. -Vol. 110, N 11. Abstr. 735.
- Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia patients with imatinib resistance and intolerance / P. Le Coutre, F. Giles, J. Apperley et al. // Blood. 2007. — Vol. 110, N 11. — Abstr. 471.
- O’Brien, S.G. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia / S.G. O’Brien, M.W. Deininger // Sem. Hematol. 2003. -Vol. 40, N 2. Suppl 2. — P. 26−30.
- Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate / C. Schoch, T. Haferlach, W. Kern et al. // Leukemia. 2003. — Vol. 17, N 2. — P. 461−463.
- Outcome of patients with Philadelphia positive chronic myelogenous leukemia post-imatinib mesylate failure / H.M. Kantarjian, S. O’Brien, M. Talpaz et al. // Cancer. 2007. — Vol. 109, N8.-P. 1556−1560.
- Oztas, P. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia / P. Oztas, S. Erbasi // J. Acta Derm. Venereol. 2006. — Vol. 86, N 2. -P. 174−175.
- Pearse, A.G.E. Histochemistry, theoretical and applied / A.G.E. Pearse. 3rd ed. -Edinburg: Churchill Livingstone, 1968. — Vol. 1. — 759 p.
- Peng, B. Clinical pharmacokinetics of imatinib / B. Peng, P. Lloyd, H. Schran // J. Clin. Pharmacokinet. 2005. — Vol. 44, N 9. — P. 879−894.
- Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients / B. Peng, M. Hayes, D. Resta et al. // J. Clin. Oncol. 2004. — Vol. 22, N 5. — P. 935−942.
- Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: A study by the National Cancer Institute Organ Dysfunction Working Group / R.K. Ramanathan, J.
- Gibbons, M.J. Egorin et al. // J. Clin. Oncol. 2008. — Vol. 26, N 4. — P. 570 576.
- Philadelphia chromosome positive leukemias: from basic mechanisms to molecular theurapeutics / R. Kurzrock, H.M. Kantarjian, B J. Druker, M. Talpaz // Ann. Int. Med.-2003.-Vol. 138, N 10.-P. 819−830.
- Pleuralpericardic effusion as uncommon complication in CML patients treated with Imatinib / M. Breccia, G.M. D’Elia, M. D’Andrea et al. // Eur. J. Haematol. 2005. — Vol. 74, N 1. — P. 89−90.
- Practical management of patients with chronic myeloid leukemia receiving imatinib / M.W. Deininger, S.G. O’Brien, J.M. Ford et al. // J. Clin. Oncol. -2003. Vol. 21, N 8. — P. 1637−1647.
- Preclinical characterization of the selective JAK½ inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms / A. Quintas-Cardama, K. Vaddi, P. Liu et al. // Blood. 2011. — Vol. 118, N 2. -P. 401−408.
- Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI 571 in vitro / S.M. Gruham, H.G. Jorgensen, E. Allan et al. // Blood. 2002. — Vol. 99, N 1. — P. 319−325.
- Prognostic discrimination in «good-risk» chronic granulocytic leukemia / J.E. Sokal, E.B. Cox, M. Baccarani et al. // Blood. 1984. — Vol. 63, N 4. — P. 789.
- Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa / D. Marin, S. Marktel, M. Bua et al. // Leukemia. 2003. — Vol. 17, N 8. — P. 1448−1453.
- Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy / J.E. Cortes, M. Talpaz, F. Giles et al. // Blood. 2003. — Vol. 101, N 10. — P. 3794−3800.
- Prognostic significance of the morphological dysplastic changes in chronic myelogenous leukemia / T. Matsuo, M. Tomonaga, K. Kuriyama et al. // Leukemia Research. 1986. -Vol. 10, Issue 3,-P. 331−337.
- Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia / R. Hehlmann, H. Heimpel, J. Hasford et al. // Blood. 1994. — Vol. 84, N 12. — P. 4064−4077.
- Real Life Rates of Disease Monitoring in Clinical Practice in Europe / E. Morra, M. Michallet, J. Steegmann et al. // Blood. 2007. — Vol. 118, N 1. — P. 582a.
- Rohrbacher, M. Epidemiology of chronic myeloid leukaemia (CML) / M. Rohrbacher, J. Hasford // Best Pract. Res. Clin. Haematol. 2009. — Vol. 22, N 3. -P. 295−302.
- Rosti, G. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate / G. Rosti, G. Martinelli, M. Baccarani // Nat. Med. 2007. — Vol. 13, N 1. — P.15.
- Ryan, M. Inhibition of Imatinib Transport by Uremic Toxins During Renal Failure / M. Ryan, F.A. Sparreboom // J. of Clin. Oncol. 2008. — Vol. 26, N 25. — P. 4226−4227.
- Schoeffski, P. Sunitinib and Hypothyroidism / P. Schoeffski, P. Wolter, U. Himpe //N. Engl. J. Med.-2007.-Vol. 356, N 15.-P. 1580−1581.
- SEER Cancer Statistics Review, 1975—2001 / L.A.G. Ries, M.P. Eisner, C.L. Kosary et al.//Cancer.-2004.-Vol. 101, Issue 1.-P. 3−27.
- Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib / A.S. Corbin, P.L. Rosee, E.P. Stoffregen et al. //Blood. -2003. -Vol. 101, N 11.-P. 4611−4614.
- Severe hemolytic anemia and skin reaction in a patient treated with imatinib / J. De Arriba, C. Nerin, E. Garcia et al. // J. Ann Oncol. 2003. Vol. 14. — P. 962.
- Severe hepatitis and complete molecular response causedby imatinib mesylate: possible association of its concentrationwith clinical outcomes / S. Kikuchi, K. Muroi, S. Takahashi et al. // J. Leukemia Lymphoma. 2004. — Vol. 45, N 11. -P. 2349−2351.
- Sheehan, H.L. An improved method of Staining Leukocyte Granules with Sudan Black B / H.L. Sheehan, G.W. Storey // J. of Pathol, and Bacteriol. 1947. — Vol. 59, N2.-P. 336−339.
- Shepherd, P.C. Severe cytopenia with sequential use of busulphan and interferon alpha in chronic myeloid leukemia / P.C. Shepherd, S. Richards, N.C. Allen // Br. J. Haematol. 1994. — Vol. 86, N 1. — P. 92−96.
- Sideroblastic anemia following treatment of chronic myeloid leukemia with busulfan / S.M.M. Magalhaes, F.B. Duarte, S.C.C. Ribeiro et al. // Leukemia. -2000.-Vol. 14, N1.-P. 214−215.
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia / A. Hochhaus, S.G. O’Brien, F. Guilhot et al. // Leukemia. 2009. — Vol. 23, N6.-P. 1054−1061.
- Sprycel (dasatinib) package insert., Princeton, NJ: Bristol-Myers Squibb Company, 2009.
- Staging and prognosis in chronic myelogenous leukemia / J.E. Sokal, M. Baccarani, D. Russo, S. Tura // Semin. Hematol. 1988. — Vol. 25, N 1. — P. 4961.
- Staging of chronic myeloid leukemia in the imatinib era / J.E. Cortes, M. Talpaz, S. O’Brien et al. // Cancer. 2006. — Vol. 106, N 6. — P. 1306−1315.
- Sunitinib-Induced Autoimmune Thyroiditis in a Patient with Metastatic Renal Cell Carcinoma: A Case Report / T. Babacana, A. Sevincb, E. Akarsub, O. Balakanb // Chemotherapy. 2012. — Vol. 58. — P. 142−145.
- Sunitinib-related thyroid dysfunction: A single-center retrospective and prospective evaluation / P. Schoeffski, P. Wolter, U. Himpe et al. // J. of Clin. Oncol. 2006. — Vol. 24, Suppl 18. ASCO Annual Meeting Proceedings. Part I. -P. 3092.
- Testing for chronic kidney disease: a position statement from the National Kidney Foundation / J.A. Vassalotti, L.A. Stevens, A.S. Levey et al. // Am. J. Kidney. Dis.- 2007. -Vol. 50, N2.-P. 169−180.
- The c-Abl Tyrosine Kinase Is Regulated Downstream of the B Cell Antigen Receptor and Interacts with CD 19 / P.A. Zipfel, M. Grove, K. Blackburn et al. // The J. of Immunol. 2000. — Vol. 165. N 12. — P. 6872−6879.
- The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase / T.B. Sneed, H.M. Kantarjian, M. Talpaz et al. // Cancer. 2004. — Vol. 100, N 1. — P. 116−121.
- The specific enhancement of interferon-alpha induced growth inhibition by BCRYABL only occurs in multipotent cells / A. Pierce, D.L. Smith, L.V. Jacobsen et al. // J. Hematol. 2001. — Vol. 2, N 4. — P. 257- 264.
- The tyrosine Kinese inhibitor CGP571148 B selectivly ingibits the grouth of BCR-ABL positive cells / M.W. Deininger, G.J. Goldman, N. Lydon, J.V. Melo // Blood. 1997. — Vol. 90, N 9. — P. 3691−3698.
- Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia / T.D. Kim, M. Schwarz, H. Nogai et al.//Thyroid. 2010. — Vol. 20, N 11.-P. 1209−1214.
- Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor sti571 results in marked regression of bone marrow fibrosis / C. Beham-Schmid, U. Apfelbeck, H. Sill et al. //Blood. 2002. — Vol. 99.-P. 381−383.
- Treatment with m-TOR ingibitor, everolimus (RAD001) overcomes resistance to imatinib in Phleukemia quiescent or T315I mutated cells / Y. Minami, A.M. Lowell, C.L. Borgman et al. // Blood. 2009. — Vol. 11, N 22. — Abstr. 3277.
- Treatment with nilotinib for patients with chronic myeloid leukemia who failed prior therapy with imatinib and dasatinib / E. Jabbour, H. Kantarjian, F. Giles et al. //Blood.-2006.-Vol. 108.-Abstr. 7038.
- Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia / S. Picard, K. Titier, G. Etienne et al. // Blood. 2007. — Vol. 109, N 8. — P. 3496−3499.
- Tsang, J. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM) / J. Tsang, L. Rudychev, S.L. Pescatore // Clin. Oncol. 2006. -Vol. 24, N 18.-P. 6119.
- Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia / J.M.A. Daniels, A. Vonk-Noordegraaf, J.J. Janssen et al. // ERJ. 2009. — Vol. 33, N3,-P. 670−672.
- Tyrosin kinase activity and transformation potency of bcr-abl oncogene products / T.G. Lugo, A.M. Pendergast, A.J. Muller et al. // Science. 1990. — Vol. 247, N 4946.-P. 1079−1082.
- Tyrosine Kinase Inhibitors Noncompetitively Inhibit MCT8-Mediated Iodothyronine Transport / D. Braun, T.D. Kim, P. le Coutre et al. // The J. of Clin. Endocrinol. &Metabol.-2012.- Vol. 97, N l.-P. 1837.
- Van Etten, R.A. Cycling, stressed-out and nervous: cellular functions of c-abl / R.A. Van Etten // Trend. Cell. Biol. 1999. — Vol. 9, N 5. — P. 179−186.
- Vitiligo-like lesions in an adult patient treated with Imatinib mesylate / C. Cerchione, R. Fabbricini, F. Pane et al. // J. Leuk. Res. 2009. — Vol. 33, N 8. -P. 104−105.
- Wang, L. Evidence that PPar activation may control the expression of the imatinib transporter hOCT 1 in chronic myeloid leukemia / L. Wang, M. Austin, E. Clark // Haematologica. 2008. — Vol. 1. — P. 44. — abstr. O 111.
- Woo, S.M. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib / S.M. Woo, C.H. Huh // Dermatol. 2007. — Vol. 34, N 10. -P. 724−726.